ResearchSafe

Tbh the new tadalafil‑peptide conjugate: hype vs real benefits?

Posted by hank_m in Research & News - 5 points, 5 comments.

I just skimmed a 2024 paper in the Journal of Controlled Release that finally put the Tadalafil‑Peptide Conjugate on the map, and i’m curious how the community feels about it, bc the idea of targeting PDE5 inhibition just to the penis with a CPP sounds like a game‑changer, but i’m also wary of the hype. Atoi of regular tadalafil. I’ve been using the daily low‑dose for a while, and the headache has definitely been a pain point; i’m tempted to try the conjugate if it’s available, but i’d love to hear if anyone’s got any early anecdotal data or even a lab trial they’re following.

Could this actually be the “weekend pill” with fewer side effects, or is it just a clever marketing angle? Tbh i’d love to know what you think.

Comments

  • tara_ironman: I’ve read the paper too – it’s a clever idea, but I haven’t seen any human data yet. From what I know, the conjugate is still in animal studies or early phase trials, so we don’t have real‑world reports on side‑effects or efficacy. Your headache with daily tadalafil might be from systemic exposure, and a targeted delivery could help, but until somebody publishes a small human study we’re guessing. Do you know if any clinic is running a trial? If it stays in pre‑clinical stage, it’s more marketi
  • hank_m: Thanks for the quick read, i’ve also seen that the conjugate is still just in pre‑clinical animal work, so there isn’t any clinic‑level data yet, and that’s why my own guess is the same as yours. I’m checking a few research‑hospital sites in the US and Europe, anyone else know of a phase‑I human trial coming up? I’d love to link once it’s posted.
  • hank_m: Tbh i’m not aware of any clinic running a human trial yet, i think they’re still wrapping up the animal work, so it’s still more hype than evidence at the moment, you might keep the low‑dose daily unless you want to try a different PDE5 blocker to see if the headache clears up. Has anyone seen a PR about a first‑in‑human study?
  • grace_sleepnerd: I haven’t heard of a first‑in‑human PR either, so I’m still on the low‑dose daily. If any of y’all see a clinical study or a credible preprint, drop it in. It would help me decide if I should switch to the conjugate or just keep the regular tadalafil.
  • hank_m: Thanks for the heads up, grace_sleepnerd, i’ve only skimmed the 2024 JCR paper – it’s all in mouse models and no first‑in‑human data yet, so i’m still on the low‑dose daily, just as you are, and that headache still bugs me. I’ll keep an eye on any peer‑reviewed preprint or clinical trial report and drop it here as soon as i spot it, so you can make a better switch decision when the time comes. Any particular symptom you’re watching for on the daily dose?

Community discussion - research and educational context only. Not medical advice.